- Conditions
- Neuromuscular Blockade
- Interventions
- Group A. "Muscle relaxant #1": rocuronium + sugammadex; "Muscle relaxant #2": succinylcholine +saline, Group B. "Muscle relaxant #2": succinylcholine +saline; "Muscle relaxant #1": rocuronium + sugammadex;
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1225–1248
of 1,574
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Vertigo, Dizziness, Nausea, Balance
- Interventions
- Transcranial vibrating system, Transcranial vibrating system sham
- Device
- Lead sponsor
- Otolith Labs
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 2
- States / cities
- Rockville, Maryland
- Conditions
- Ovarian Cancer
- Interventions
- Message-based Outreach Intervention for Survivors, Standard Outreach for Survivors, Message-based Outreach Intervention for Close Relatives, Standard Outreach for Close Relatives
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,331 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Healthy Participants
- Interventions
- AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Glendale, California • Brooklyn, Maryland
- Conditions
- Relative Bioavailability
- Interventions
- BDA MDI 160/180 mcg, Pulmicort Flexhaler 180 mcg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Cognitive Decline, Mucopolysaccharidosis I, Hurler-Scheie Syndrome, Scheie Syndrome, Lysosomal Storage Disease
- Interventions
- laronidase
- Drug
- Lead sponsor
- Patricia I. Dickson, M.D.
- Individual
- Eligibility
- 6 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 3
- States / cities
- Oakland, California • Torrance, California • Minneapolis, Minnesota
- Conditions
- Stroke, Stroke, Acute, Stroke, Ischemic
- Interventions
- AER-271, Placebo
- Drug
- Lead sponsor
- Aeromics, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Sonelokimab (M1095), Adalimumab, Placebo
- Drug · Other
- Lead sponsor
- MoonLake Immunotherapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 15
- States / cities
- Fountain Valley, California • Los Angeles, California • Miami, Florida + 12 more
- Conditions
- Circadian Rhythm Sleep Disorder of Shift Work Type, Metabolic Disease, Insulin Sensitivity
- Interventions
- Time-restricted feeding, Circadian Misalignment
- Behavioral
- Lead sponsor
- Colorado State University
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Osteoarthritis, Knee
- Interventions
- Naproxen Sodium (Aleve, BAY117031), Acetaminophen ER, Celecoxib, Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 5
- States / cities
- Chandler, Arizona • Pinellas Park, Florida • Chicago, Illinois + 2 more
- Conditions
- Healthy Participants
- Interventions
- Ruxolitinib IR, Ruxolitinib XR
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- AB680, Zimberelimab, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 9
- States / cities
- Santa Monica, California • St Louis, Missouri • New York, New York + 5 more
- Conditions
- Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma, Locally Advanced Melanoma, Locally Advanced Solid Neoplasm, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Non-Small Cell Lung Carcinoma, Stage IB Lung Cancer AJCC v7, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Abexinostat, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Rahul Aggarwal
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- HER2-Positive Early Breast Cancer
- Interventions
- Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC), Pertuzumab IV, Trastuzumab IV
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 9
- States / cities
- Lakewood, Colorado • Peoria, Illinois • Wichita, Kansas + 5 more
- Conditions
- Multiple Sclerosis, Clinically Isolated Syndrome
- Interventions
- Ocrelizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- San Francisco, California • Aurora, Colorado • Chicago, Illinois + 3 more
- Conditions
- Type2 Diabetes, Cardiovascular Diseases
- Interventions
- Dapagliflozin, Glimepiride
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Healthy
- Interventions
- Product B® IsaGenesis®, IsaGenesis®
- Dietary Supplement
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Myeloid Leukemia, Chronic, Chronic Phase
- Interventions
- Ponatinib
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 16
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 12 more
- Conditions
- Long QT Syndrome
- Interventions
- LQT-1213, Placebo
- Drug · Other
- Lead sponsor
- Thryv Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Healthy Participants
- Interventions
- Staccato Alprazolam, Midazolam, Diazepam
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 20 Years to 55 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- B-cell Lymphoma
- Interventions
- Glofitamab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Vaping
- Interventions
- Control task and Trier Social Stress Task
- Other
- Lead sponsor
- Clemson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Diabetes Mellitus
- Interventions
- Insulin Lispro, Regular Human Insulin, rHuPH20
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Professional Quality of Life
- Interventions
- Mindfulness and Sleep Hygiene, Phyical activity and Sleep Hygiene
- Behavioral
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia